Author:
Tereshchenko L. V.,Latanov A. V.
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Armstrong, R. A., “Parkinson’s disease and the eye,” Ophthal. Physiol. Opt., 17, Suppl. 2, S9–S16 (1997).
2. Armstrong, R. A., “Visual symptoms in Parkinson’s disease,” Parkinsons Dis., 2011, Art. ID 908306 (2011), doi: 10.4061/2011/908306.
3. Baziyan, B. Kh., Chigaleichik, L. A., and Dmitriev, I. E., “Possible mechanisms of impairment of saccadic eye movements in patients with Parkinson’s disease,” Byul. Eksperim. Biol, 125, No. 3, 254–259 (1998).
4. Benazzouz, A., Gross, C., Dupont, J., and Bioulac, B., “MPTP induced hemiparkinsonism in monkeys: behavioral, mechanographic, electromyographic and immunohistochemical studies,” Exp. Brain Res., 90, No. 1, 116–120 (1992).
5. Bezard, E., Dovero, S., Prunier, C., et al., “Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson’s disease,” J. Neurosci., 21, No. 17, 6853–6861 (2001).